ExploreWatchlistsPricing
  1. JP-listed companies
  2. SymBio Pharmaceuticals Limited
  3. Financials
  4. Operating income

SymBio Pharmaceuticals Limited (4582)

Market cap
¥6.6B
P/E ratio
-1.3x
Symbiopharm develops drugs for rare diseases in cancer and viral infections, focusing on compounds with proven human efficacy to reduce development risks.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating income (Million JPY)YoY (%)
Dec 31, 2025-4,441+14.54%
Dec 31, 2024-3,877+377.65%
Dec 31, 2023-812-141.34%
Dec 31, 20221,964+93.27%
Dec 31, 20211,016-122.55%
Dec 31, 2020-4,506+4.76%
Dec 31, 2019-4,302+61.95%
Dec 31, 2018-2,656-32.71%
Dec 31, 2017-3,947+85.57%
Dec 31, 2016-2,127-16.64%
Dec 31, 2015-2,552+95.79%
Dec 31, 2014-1,303

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat